Related Experiment Videos
Insights
Severe hyperactivity affects 0.5-1.4% of children. While behavioral approaches are primary, stimulant medications like methylphenidate are reassessed for severe or treatment-resistant childhood hyperactivity cases.
Area of Science:
- Pediatric Neurology
- Child Psychology
- Pharmacology
Background:
- Severe hyperactivity, characterized by impulsivity, inattention, and overactivity, affects an estimated 0.5-1.4% of school-aged children in England and Wales.
- Central nervous system (CNS) stimulants, methylphenidate and dexamfetamine, are licensed in the UK for treating childhood hyperactivity when non-drug measures are insufficient.
Purpose of the Study:
- To reassess the role and efficacy of stimulant medications in the management of severe childhood hyperactivity.
- To evaluate the current standing of stimulant drugs as a treatment option for children with severe hyperactivity.
Main Methods:
- This study involves a reassessment of previous conclusions regarding the treatment of severe hyperactivity in children.
- The methodology focuses on evaluating the place of stimulant drugs in clinical practice.
Main Results:
- Previous findings in 1995 indicated that behavioral and educational approaches should be the first-choice treatments for most children with hyperactivity.
- Stimulant drugs were recommended to be reserved for children with severe hyperactivity or those resistant to non-drug interventions.
Conclusions:
- The study re-examines the established guidelines for using stimulant medications in pediatric hyperactivity.
- It aims to provide updated perspectives on the therapeutic positioning of methylphenidate and dexamfetamine for severe cases.
Abstract:
It is estimated that 0.5-1.4% of school-aged children in England and Wales have severe hyperactivity, a syndrome characterised by impulsiveness, inattention and overactivity. In the UK, two CNS stimulants, methylphenidate and dexamfetamine (dexamphetamine), are licensed for treating childhood hyperactivity where non-drug measures along have proved insufficient. In 1995, we concluded that behavioural and educational approaches should be first-choice steps in most children with hyperactivity, with stimulant drugs being reserved for children in whom the disorder is severe or who are resistant to non-drug treatments. Here, we reassess the place of stimulant drugs in the management of severe hyperactivity in children.